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CORRECTION 
Pepine C J, Geiler NL, Knatterud GL, et al. The Asymptomatic 
Cardiac lschemia Pilot (ACIP) study: design of a randomized 
clinical trial, baseline data and implications for a long-term 
outcome trial. J. Am Coil Cardiol 1994;24:1-10. 
Knatterud GL, Bourassa MG, Pepine C J, et ai. Effects of 
treatment strategies to suppress ischemia in patients with 
coronary, arteu diseasc: 12-week results of the Asymptomatic 
Cardiac Ischemia Pilot (ACIP) study. J Am Coil Cardiol 
1994;24:11-20. 
In the July 1994 issue of the Journal, the Asymptomatic 
Cardiac Ischemia Pilot (ACIP) Study Investigators published 
two reports, one on the design of the study and the other on 
the 12-week results of the ACIP Study. As part of the final 
editing of the data, the Clinical Coordinating Center stall 
discovered inconsistencies in the reporting of baseline charac- 
teristics in one clinical unit. As a result, an audit visit was 
conducted, and the records for all 60 patients enrolled in this 
clinical unit were examined. The audit determined that there 
was evidence of unacceptable p rformance in the conduct of 
the trial at this unit. Briefly, a number of the enrolled patients 
were not eligible to be randomized, and treatment plans were 
frequently made for patients before randomization and fob 
lowed irrespective of randomized treatment assignment. Thc 
conclusion was that he data from this unit were not of acceptable 
quality and that the data from this unit could not be considered 
comparable to the data from the other clinical units. Therefore, 
the audit team recommended that no data from this clinical unit 
should be included in future analyses or publications. The ACIP 
Data and Safety Monitoring Board reviewed the audit report 
without knowledge of the Audit Committee r commendation and 
came to the identical conclusion. 
All analyses presented in the two reports published in July 
1994 have been repeated excluding patients from this clinical 
unit. We found that there were essentially no changes in the 
reported findings (Table 1). Thus, the conclusion in the 1994 
ACIP report by Knatterud et al. that the pilot study demon- 
strated that cardiac ischemia can be suppressed in 40% to 55% 
of patients with either low or moderate doses of medication or 
revascularization and that a large trial is feasible are still valid. 
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Table 1. ACIP Outcomes 
11 Clinical Units 
Angina- lschemia- 
Guided Guided 
Slratcgy Strategy Rcvasc 
10 Clinical Units 
Angina- lschemia- 
Guided Guided 
p Value Strategy Strategy Revasc p Value 
No. of pts enrolled 204 202 
Primary outcome 
(no ischemia or eventsl 
12 wk 383] 41.3 
6 mo 3~.8 43.0 
12 mn 31.8 37.0 
Death or MI 
12 wk 1.5 l.[J 
6 mo 4.4 4,11 
12 mo ~.8 5.~J 
Death, MI, PTCA or CABG 
12 wk 5.~) 3.0 
6 mo 10.3 75) 
12 mo 17.2 14.4 
212 183 183 192 
54.7 0.11114 38.6 41.4 53.6 0.01 
555] 11.(1113 39.2 41.5 54.9 0.005 
57.3 0.001 3(I.9 35.6 56.7 < 0.001 
I .q 0.74 1.6 1. I 2.1 0.74 
I.q 0.33 3.8 4.4 2.1 0.46 
2.4 [~.I~2 8.8 6.0 2.6 0.04 
5.2 0.35 4.4 2.7 5.2 0.46 
7.5 0.56 8.2 8.2 7.8 0.99 
q.9 0.10 15.9 13.7 9.9 0.26 
Data presented are number or perccn| of patients (ptsl. CABG c~mmary arte U bypass graft surgery: MI - myocardial 
transluminal coronary angioplasty: Re~a,c : rc~ascularization. 
infarction; PTCA = percutaneous 
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